Effectiveness and Safety of High- vs Low-Dose Swallowed Topical Steroids for Maintenance Treatment of Eosinophilic Esophagitis: A Multicenter Observational Study.
Esophagus
Long-Term Outcome
Relapse
Response to Therapy
Swallowed Topical Corticosteroids
Journal
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
ISSN: 1542-7714
Titre abrégé: Clin Gastroenterol Hepatol
Pays: United States
ID NLM: 101160775
Informations de publication
Date de publication:
12 2021
12 2021
Historique:
received:
06
07
2020
revised:
04
08
2020
accepted:
11
08
2020
pubmed:
18
8
2020
medline:
27
1
2022
entrez:
18
8
2020
Statut:
ppublish
Résumé
Data evaluating efficacy of different doses of swallowed topical corticosteroids (STC) in the long-term management of eosinophilic esophagitis (EoE) are lacking. We assessed long-term effectiveness and safety of different STC doses for adults with EoE after achievement of histological remission. We performed a retrospective multicenter study at five EoE referral centers (US and Switzerland). We analyzed data on 82 patients with EoE in histological remission and ongoing STC treatment with therapeutic adherence of ≥75% (58 males; mean age at diagnosis, 37.2±14.4 years). Patients were followed for a median of 2.2 years (interquartile range [IQR], 1.0-3.8 years). We collected data from 217 follow-up endoscopy visits. The primary endpoint was time to histological relapse. Histological relapse occurred in 67% of patients. Relapse rates were comparable in patients taking low dose (≤0.5 mg per day, n = 58) and high dose STC (>0.5 mg per day, n = 24) with 72 vs 54% (ns). However, histological relapse occurred significantly earlier with low dose STC (1.0 vs 1.8 years, P = .030). There was no difference regarding rates of and time to stricture formation for low vs high dose STC. Esophageal candidiasis was observed in 6% of patients (5% for low dose, 8% for high dose, ns). No dysplasia or mucosal atrophy was detected. Histological relapse frequently occurs in EoE despite ongoing STC treatment regardless of STC doses. However, relapse develops later in patients on high dose STC without an increase in side-effects. Doses higher than 0.5 mg/day may be considered for EoE maintenance treatment, but advantage over lower doses appears to be small.
Sections du résumé
BACKGROUND & AIMS
Data evaluating efficacy of different doses of swallowed topical corticosteroids (STC) in the long-term management of eosinophilic esophagitis (EoE) are lacking. We assessed long-term effectiveness and safety of different STC doses for adults with EoE after achievement of histological remission.
METHODS
We performed a retrospective multicenter study at five EoE referral centers (US and Switzerland). We analyzed data on 82 patients with EoE in histological remission and ongoing STC treatment with therapeutic adherence of ≥75% (58 males; mean age at diagnosis, 37.2±14.4 years). Patients were followed for a median of 2.2 years (interquartile range [IQR], 1.0-3.8 years). We collected data from 217 follow-up endoscopy visits. The primary endpoint was time to histological relapse.
RESULTS
Histological relapse occurred in 67% of patients. Relapse rates were comparable in patients taking low dose (≤0.5 mg per day, n = 58) and high dose STC (>0.5 mg per day, n = 24) with 72 vs 54% (ns). However, histological relapse occurred significantly earlier with low dose STC (1.0 vs 1.8 years, P = .030). There was no difference regarding rates of and time to stricture formation for low vs high dose STC. Esophageal candidiasis was observed in 6% of patients (5% for low dose, 8% for high dose, ns). No dysplasia or mucosal atrophy was detected.
CONCLUSION
Histological relapse frequently occurs in EoE despite ongoing STC treatment regardless of STC doses. However, relapse develops later in patients on high dose STC without an increase in side-effects. Doses higher than 0.5 mg/day may be considered for EoE maintenance treatment, but advantage over lower doses appears to be small.
Identifiants
pubmed: 32798703
pii: S1542-3565(20)31136-8
doi: 10.1016/j.cgh.2020.08.027
pmc: PMC8108396
mid: NIHMS1671483
pii:
doi:
Substances chimiques
Glucocorticoids
0
Steroids
0
Types de publication
Journal Article
Multicenter Study
Observational Study
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2514-2523.e2Subventions
Organisme : NCATS NIH HHS
ID : U2C TR002818
Pays : United States
Organisme : NIAID NIH HHS
ID : U54 AI117804
Pays : United States
Informations de copyright
Copyright © 2021 AGA Institute. Published by Elsevier Inc. All rights reserved.
Références
Gut. 2016 Mar;65(3):390-9
pubmed: 25792708
United European Gastroenterol J. 2017 Apr;5(3):335-358
pubmed: 28507746
Clin Gastroenterol Hepatol. 2019 Feb;17(3):419-428.e6
pubmed: 29902648
Aliment Pharmacol Ther. 2015 May;41(9):797-806
pubmed: 25728929
Gastroenterology. 2013 Dec;145(6):1230-6.e1-2
pubmed: 23954315
Gastroenterology. 2010 Nov;139(5):1526-37, 1537.e1
pubmed: 20682320
J Allergy Clin Immunol. 2011 Jul;128(1):3-20.e6; quiz 21-2
pubmed: 21477849
Gastroenterology. 2019 Jul;157(1):65-73.e5
pubmed: 30872104
Allergy. 2020 Mar;75(3):727-730
pubmed: 31714997
Gastroenterology. 2017 Mar;152(4):776-786.e5
pubmed: 27889574
Gastroenterology. 2016 Mar;150(3):581-590.e4
pubmed: 26584601
Am J Gastroenterol. 2017 Oct;112(10):1527-1535
pubmed: 28719593
Gastroenterology. 2020 May;158(6):1776-1786
pubmed: 32359562
Gastroenterology. 2012 Aug;143(2):321-4.e1
pubmed: 22561055
Clin Gastroenterol Hepatol. 2011 May;9(5):400-9.e1
pubmed: 21277394
Gastroenterology. 2019 Jul;157(1):74-86.e15
pubmed: 30922997
Clin Gastroenterol Hepatol. 2018 Feb;16(2):226-233.e2
pubmed: 28987502
J Gastroenterol Hepatol Res. 2015 Oct 1;4(10):1780-1787
pubmed: 27110513
Am J Gastroenterol. 2016 Aug;111(8):1187-97
pubmed: 27325220
N Engl J Med. 2015 Oct 22;373(17):1640-8
pubmed: 26488694
Gut. 2013 Apr;62(4):489-95
pubmed: 22619364
Clin Gastroenterol Hepatol. 2020 Jun;18(7):1483-1492.e2
pubmed: 31499249
Allergy. 2014 Sep;69(9):1248-54
pubmed: 24894658
Clin Gastroenterol Hepatol. 2019 Oct;17(11):2149-2160
pubmed: 30710696
Clin Transl Gastroenterol. 2017 Jun 15;8(6):e97
pubmed: 28617448